Molnupiravir

ICMR says Molnupiravir has major safety concerns, not included in national protocol for COVID-19 treatment

Dr Balram Bhargava, director-general of ICMR, said that contraceptive methods should be used for three months if the drug is administered to women since the child may have problems

Optimus Pharma to launch anti-COVID pill Molnupiravir next week; all you need to know

Molnupiravir, developed by US-based biotechnology company Ridgeback Biotherapeutics in collaboration with US pharma giant Merck, was approved for emergency use in India on Tuesday

Centre clears two new COVID-19 vaccines Covovax, Corbevax and Merck's COVID pill for EUA

With this approval, the number of COVID-19 vaccines which have received emergency use authorisation in the country has increased to eight.

Two new antiviral drugs join the war against COVID-19; here's a look at their efficacy

COVID-19 vaccines have been successful in preventing severe disease, but the deployment of these antivirals will still be significant given that vaccines aren’t protective 100 percent of the time

UK becomes first country to approve Merck's anti-COVID-19 pill; health minister calls it 'game changer'

The antiviral, called molnupiravir, works by decreasing the ability of a virus to replicate, thereby slowing down the disease.

From Merck’s Molnupiravir to Glenmark’s nasal spray, over 20 new drugs in pipeline for COVID-19

While the market for these drugs may not be huge at present due to a drop in COVID-19 cases and extended timelines, experts believe that these drugs will help control future waves and protect people with weak immunity

Merck Pharma to sign licensing pacts with 5 Indian drug firms for COVID-19 drug candidate molnupiravir

Molnupiravir is an oral antiviral agent, currently being studied in a Phase 3 trial for the treatment of non-hospitalised COVID-19 patients

Oral antiviral drug Molnupiravir can block spread of SARS-CoV-2 virus in ferrets, study shows

Molnupiravir is now in the advanced phase, multi-centre, clinical II/III trials in human beings after successful completion of phase I safety trials.

New antiviral oral drug molnupiravir completely suppresses coronavirus transmission within 24 hours in ferrets, claims study

Researchers claim that MK-4482/EIDD-2801 or molnupiravir is the first orally available drug to quickly block SARS-CoV-2 and has the potential of being ground-breaking